1. Inflammation, Monoclonal Antibodies and Depression: Joining the Dots

   • David Hunt

   Commentary 08 May 2019 Pages: 811 - 812

2. Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation

   • Lee S. Nguyen
   • Mathieu Vautier
   • Joe-Elie Salem

   Review Article 13 March 2019 Pages: 813 - 825

   

3. Drug-Induced Photosensitivity—An Update: Culprit Drugs, Prevention and Management

   • Kim M. Blakely
   • Aaron M. Drucker
   • Cheryl F. Rosen

   Review Article 19 March 2019 Pages: 827 - 847

4. Pharmacovigilance Systems in Arab Countries: Overview of 22 Arab Countries

   • Thamir M. Alshammari
   • Neslihan Mendi
   • Yazed Alsowaida

   Review Article 20 April 2019 Pages: 849 - 868

5. Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis

   • Xiao Ding
   • Qianqian Li
   • Faming Zhang

   Short Communication 10 April 2019 Pages: 869 - 880

   

6. Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study

   • Sieta T. de Vries
   • Judy Harrison
   • Peter G. M. Mol

   Short Communication Open access 06 February 2019 Pages: 881 - 886

7. Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study

   • Lotte A. Minnema
   • Thijs J. Giezen
   • Helga Gardarsdottir

   Original Research Article Open access 08 January 2019 Pages: 887 - 895

   

8. Use of FDA’s Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure

   • Efe Eworuke
   • Emily C. Welch
   • Judith C. Maro

   Original Research Article 08 February 2019 Pages: 897 - 906

   

9. Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol

   • R. David Woosley
   • Klaus Romero
   • Raymond L. Woosley

   Original Research Article 19 March 2019 Pages: 907 - 913

10. A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia

    • Babafunso Aderemi Adenuga
    • Timothy William Rennie

    Research Letter 08 May 2019 Pages: 915 - 917

11. Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists

    • Rasmus M. Christensen
    • Christian R. Juhl
    • Signe S. Torekov

    Correction 30 April 2019 Pages: 919 - 919